A detailed history of E Fund Management Co., Ltd. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 6,350 shares of BMY stock, worth $251,840. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,350
Previous 5,619 13.01%
Holding current value
$251,840
Previous $288,000 19.44%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $35,073 - $39,766
731 Added 13.01%
6,350 $344,000
Q4 2023

Feb 06, 2024

BUY
$48.48 - $57.85 $43,728 - $52,180
902 Added 19.12%
5,619 $288,000
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $13,662 - $15,276
-236 Reduced 4.76%
4,717 $274,000
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $30,007 - $33,318
-471 Reduced 8.68%
4,953 $317,000
Q1 2023

May 11, 2023

SELL
$65.71 - $74.53 $2,694 - $3,055
-41 Reduced 0.75%
5,424 $376,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $49,100 - $58,141
-717 Reduced 11.6%
5,465 $393,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $82 - $48,947
637 Added 11.49%
6,182 $439,000
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $25,126 - $27,673
-346 Reduced 5.87%
5,545 $427,000
Q1 2022

May 12, 2022

SELL
$61.48 - $73.72 $73,468 - $88,095
-1,195 Reduced 16.86%
5,891 $430,000
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $9,170 - $10,690
171 Added 2.47%
7,086 $442,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $81,358 - $95,301
1,375 Added 24.82%
6,915 $412,000
Q1 2021

May 12, 2021

BUY
$59.34 - $66.74 $328,743 - $369,739
5,540 New
5,540 $349,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $84.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.